CClinicalTrials.gg
Enrolling by invitationNCT05953948ICMPUpdated Mar 20, 2026

Effectiveness of Intelligent Case Manage Platform in Liver Transplant Recipients

An interventional study of Intelligent Case Manage Platform (ICMP) and self-management program in Liver Transplant Disorder, Self Efficacy and Quality of Life, sponsored by Chang Gung University. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Chang Gung University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
333
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

This study is a prospective, quasi-experimental design, with an experimental group and a control group, will be created. The aims of this study are as follows: 1. Describe the self-management and information needs of liver transplant recipients, 2. Create content or modules related to the self-management of liver transplant recipients, 3. Build an intelligent case management platform, 4. Evaluate the usability of the platform, and 5. Conduct deep learning and examine the effects of the intelligent case management platform on self-efficacy, self-management, health outcomes, and health-related quality of life. Data will be collected at discharge (baseline data) and 1, 3, 6, 9, and 12 months after discharge. An estimated 133 patients will be involved in this experiment: 44 in the experimental group and 89 in the control group. Statistical package software (SPSS 22.0) will be used to analyze the data. A generalized estimation equation model will examine the differences in self-efficacy, self-management, and health-related quality of life between the experimental and control groups. Survival analysis and the Kaplan-Meier method will be used to analyze health outcomes, including hospital readmission, emergency visits, episodes of infection and rejection of organs, and death.

Read the detailed description

Background: Liver transplant recipients require proper self-management to avoid the risk of various complications, reduce hospital readmission and medical costs, and improve their quality of life. They also face diverse challenges in self-management. Therefore, enhancing the self-management of liver transplant recipients after liver transplantation is important. Hospitals and medical facilities taking care of such patients should facilitate individualized care, access to healthcare resources, and planned post-discharge support. The use of information technology, artificial intelligence, and deep learning to identify and confirm the characteristics and types of self-management requirements of liver transplant recipients and provide individualized self-management may help improve their self-management skills and health outcomes. The quality and continuity of care can also be improved. However, no studies have been conducted in this regard.

Purpose: To establish an intelligent case management platform that combines artificial intelligence and deep learning to enhance the self-efficacy and self-management of liver transplant recipients, thereby improving clinical outcomes and health-related quality of life. The aims of this study are as follows: 1. Describe the self-management and information needs of liver transplant recipients, 2. Create content or modules related to self-management of liver transplant recipients, 3. Build an intelligent case management platform, 4. Evaluate the usability of the platform, and 5. Conduct deep learning and examine the effects of the intelligent case management platform on self-efficacy, self-management, health outcomes, and health-related quality of life.

Methods and materials: This study is a prospective, quasi-experimental design, with an experimental group and a control group, will be created. First, the self-management care and information needs of liver transplant patients will be integrated to create the foundation of the intelligent case management platform. For this purpose, an estimated 50 liver transplant recipients and 10 medical staff will be interviewed. The data will be analyzed by qualitative content analysis. Based on these contents, the intelligent case management platform will be developed and evaluated. For the evaluation, data from 200 liver transplant recipients will be collected to assess platform availability, performance, and usage status. Data related to the recipient's use of the platform and reception of self-management from the platform will also be collected for deep learning. The importance and clinical relevance of self-management provided by the platform will be assessed by the medical staff involved in liver transplant care. Deep learning techniques will be utilized, and the effectiveness of the intelligent case management platform in terms of self-efficacy, self-management, health outcomes, and health-related quality of life will be examined. An estimated 133 patients will be involved in this experiment: 44 in the experimental group and 89 in the control group. Data will be collected at discharge (baseline data) and 1, 3, 6, 9, and 12 months after discharge from the hospital. Statistical package software (SPSS 22.0) will be used to analyze the data. A generalized estimation equation model will analyze the differences in self-efficacy, self-management, and health-related quality of life over time between the experimental and control groups. This study proposes innovative applications for information technology, deep learning, and artificial intelligence. It is hoped that multidisciplinary cooperation can improve liver transplant recipients' self-management and health outcomes.

02

Conditions studied

  • Liver Transplant Disorder
  • Self Efficacy
  • Quality of Life

Keywords

  • liver transplantation
  • self-efficacy
  • self-management behavior
  • health-related quality of life
03

In context

Lead sponsor

Chang Gung University is the lead sponsor of 63 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Liver transplant recipients
  • Age 20 years and above
  • Ability to use smart-phone

Exclusion criteria

Exclusion Criteria:

  • liver encephalopathy
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
333 participants (estimated)

Study arms

  • Experimental
    Intelligent case manage platform (ICMP) and self-management program

    The experimental group received ICMP information. They could interact with the care manager via chatbot. The ICMP was established with information related to care instruction after liver transplantation.

    Other: Intelligent Case Manage Platform (ICMP) and self-management program

  • No intervention
    usual care

    Participants in the control only received the usual care that included wound care, medication, and infection control.

Interventions

  • OtherIntelligent Case Manage Platform (ICMP) and self-management program

    This platform includes information and instruction related to the care of liver transplantation. Participants could gain knowledge and skill to manage their conditions after liver transplantation.

06

What researchers measure

Primary outcomes

  1. Change of the score of self-management behavior

    Change of the score of self-management behavior related to the care after liver transplantation assessed by the Self-Management Behavior Scale

    Time frame: Chang of the score from baseline self-management behavior at 1, 3, 6, 9, and 12 months after liver transplantation

  2. Change of the score of self-efficacy

    Change of the score of self-efficacy about manage the condition after liver transplantation assessed by the Self-Efficacy Scale

    Time frame: Chang of the score from baseline self-efficacy at 1, 3, 6, 9, and 12 months after liver transplantation

  3. Change of the score of health-related quality of life

    Change of the score of health-related quality of life assessed by the questionnaire of Medical Outcome Survey - Short Form 12 (MOS SF-12)

    Time frame: Chang of the score from baseline health-related quality of life at 1, 3, 6, 9, and 12 months after liver transplantation

07

Study locations

1 site
  • Chang Gung University
    Taoyuan, TY 33302, Taiwan
08

References and documents

Individual participant data

Plan to share: No — We could not share the individual data because of the privacy.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05953948
Lead sponsor
Chang Gung University
Responsible party
Weng, Li-Chueh (Professor, Chang Gung University) — Principal investigator
First posted
Jul 20, 2023
Start date
Feb 1, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 20, 2026

Study contacts

Li-Chueh Weng, PHD
principal investigator · Chang Gung University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion